首页 | 本学科首页   官方微博 | 高级检索  
检索        

棘刺锚参抗肿瘤因子抗肿瘤作用的实验研究
引用本文:沈先荣,栾洁,蒋定文,陈伟,刘李娜,陆敏,贾福星.棘刺锚参抗肿瘤因子抗肿瘤作用的实验研究[J].中华航海医学与高气压医学杂志,2008,15(4).
作者姓名:沈先荣  栾洁  蒋定文  陈伟  刘李娜  陆敏  贾福星
作者单位:海军医学研究所,上海,200433
摘    要:目的 研究棘刺锚参抗肿瘤因子(Protankyra Bidentata anti-tumor factor,PBATF)在动物水平的抗肿瘤作用.方法 采用小鼠H22肝癌模型、大鼠Walker-256癌肉瘤模型、人体LAX肺腺癌模型、人体QGY肝癌模型,分别测定PBATF对不同肿瘤生长的抑制效应.各种模型分别设PBATF高(5 mg/kg)、中(1 mg/ks)、低(0.5 mg/kg)剂量组、阳性对照组(CTX)和阴性对照组.试验组及阳性对照组昆明种小鼠或Wiser大鼠每组均10只,裸小鼠每组均6只,阴性对照组每次各为2组.腹腔注射给药,每天1次,连续7~10 d.采用常规方法测定PBATF腹腔注射的LD50.结果 PBATF对大鼠Walker-256癌肉瘤的抑瘤率,高剂量组62.63%、中剂量组52.31%、低剂量37.49%.PBATF对人体LAX肺腺癌的抑瘤率,高剂量组56.02%、中剂量组50.60%、低剂量组40.36%.PBATF对人体QGY肝癌的抑瘤率,高剂量组52.07%、中剂量组45.56%、低剂量组33.14%.PBATF对小鼠H22肝癌的抑瘤率,高剂量组59.25%、中剂量组57.74%、低剂量组45.28%.PBATF腹腔注射给药,小鼠的LD50为1.973 g/kg.结论 获得了高纯度的PBATF,能够显著抑制体内外肿瘤生长.

关 键 词:棘刺锚参  肝癌  肺腺癌  癌肉瘤  肿瘤治疗

Experimental study of effects of Protankyra Bidentata anti-tumor factor on tumor growth
SHEN Xian-rong,LUAN Jie,JIANG Ding-wen,CHEN Wei,LU Li-na,LU Min,JIA Fu-xing.Experimental study of effects of Protankyra Bidentata anti-tumor factor on tumor growth[J].Chinese Journal of Nautical Medicine and Hyperbaric Medicine,2008,15(4).
Authors:SHEN Xian-rong  LUAN Jie  JIANG Ding-wen  CHEN Wei  LU Li-na  LU Min  JIA Fu-xing
Abstract:Objective To study the inhibitory effects of Protankyra Bidentata anti-tumor factor(PBATF)on the growth of tumors implanted in mice or rats.Methods Methods of H22 liver cancer implanted in Kunming mice,Walker-256 sarcoma implanted in Wistar rats,human LAX lung cancer and human QGY liver cancer implanted in nest mice were used to detect the inhibitory effects of PBATF on the tumor growth,respectively.Animals in each model were divided into 5 groups:hish PBATF group(5 mg/kg),middle PBATF group(1 mg/kg),low PBATF group(0.5 mg/kg),positive control group(CTX)and negative control group.The preparations were administrated once a day,for 7-10 days.The LD50 peritoneal injection of PBATF was detected according to ordinary method.Results The inhibitory tumor rates of PBATF on Walker-256 sarcoma implanted in Wistar rats,human LAX lung caner implanted in nest mice,human QGY liver cancer implanted in nest mice and QGY liver cancer implanted in nest mice were 62.63%,56.02%,52.07% and 59.25% in high dose group,52.31%,50.60%,45.56% and 57.74% in middle dose group,37.49%,40.36%,33.14% and 45.28% in low dose group,respectively.The LD50 peritoneal injection of PBATF was 1.973 g/kg.Conclusions PBATF hag significant inhibitory effect on tumor growth in vivo.
Keywords:Protankyra Bidentata  Lung cancer  Liver cancer  Sarcoma  Tumor therapy
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号